Study Evaluating the Effect of Lecozotan SR on the QTc Interval

Phase 1CompletedNCT00499642

Wyeth is now a wholly owned subsidiary of Pfizer

Overview

This is a randomized, double-blind, placebo- and moxifloxacin (open-label)-controlled, 4-period crossover study.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Alzheimer Disease Healthy

Interventions

Lecozotan SRDRUG

MoxifloxacinDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Women and men aged 18 to 55 years inclusive. * Healthy as determined by the investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs, and 12-lead electrocardiogram (ECG). Exclusion Criteria: * History of any clinically important drug allergy. * Positive findings of urine drug screen (eg, amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, and opiates).

Locations (2)

Unnamed facility

Rennes, France

Unnamed facility

Rueil-Malmaison, France

Outcomes

Primary Outcomes

To assess the effect of drug administration on QTc interval.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.